PERSISTENCE WITH ANTI-TUMOR NECROSIS FACTOR THERAPIES IN PATIENTS WITH PSORIATIC ARTHRITIS IN ROUTINE PRACTICE

被引：1
|
作者：
Morel, J. [1 ]
Combe, B. [1 ]
Daien, C. [1 ]
Lukas, C. [1 ]
机构：
[1] Teaching Hosp Lapeyronie, Rheumatol, Montpellier, France
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2015年 / 74卷
关键词：
D O I：
10.1136/annrheumdis-2015-eular.4200
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0571
引用
收藏
页码：867 / 867
页数：1
相关论文
共 50 条
  • [31] Population pharmacokinetics of golumumab.: A human anti-tumor necrosis factor-α monoclonal antibody, in patients with psoriatic arthritis
    Xu, Z.
    Vu, T.
    Lee, H.
    Ling, J.
    Hu, C.
    Baker, D.
    Beutler, A.
    Pendley, C.
    Wagner, C. I.
    Davis, H. M.
    Zhou, H.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (09): : 1112 - 1112
  • [32] Risk of tuberculosis with anti-tumor necrosis factor-alpha therapy in patients with psoriasis and psoriatic arthritis in Indian population
    Sarkar, Soumajyoti
    Panda, Saumya
    Kim, Byungsoo
    Raychaudhuri, Smriti K.
    Ghosh, Asutosh
    Raychaudhuri, Siba P.
    INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY, 2020, 86 (01): : 1 - 7
  • [33] Anti-tumor necrosis factor-α therapy and changes of flow-mediated vasodilatation in psoriatic and rheumatoid arthritis patients
    Gianluigi Mazzoccoli
    Incoronata Notarsanto
    Gennaro Davide de Pinto
    Mariangela Pia Dagostino
    Angelo De Cata
    Giuseppe D’Alessandro
    Roberto Tarquini
    Gianluigi Vendemiale
    Internal and Emergency Medicine, 2010, 5 : 495 - 500
  • [34] Is There a Need for Immunopharmacologic Guidance of Anti-Tumor Necrosis Factor Therapies?
    Bendtzen, Klaus
    ARTHRITIS AND RHEUMATISM, 2011, 63 (04): : 867 - 870
  • [35] Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry
    Harrold, Leslie R.
    Reed, George W.
    Magner, Robert
    Shewade, Ashwini
    John, Ani
    Greenberg, Jeffrey D.
    Kremer, Joel M.
    ARTHRITIS RESEARCH & THERAPY, 2015, 17
  • [36] Weight changes in rheumatoid arthritis patients on anti-tumor necrosis factor agents
    Syed, Reema H.
    Gilliam, Brooke E.
    Pepmueller, Peri H.
    ARTHRITIS AND RHEUMATISM, 2007, 56 (12): : 4284 - 4284
  • [37] Genotoxicity of Anti-Tumor Necrosis Factor Therapy in Patients With Juvenile Idiopathic Arthritis
    Demirkaya, Erkan
    Cok, Ismet
    Durmaz, Emre
    Ulutas, Onur K.
    Ayaz, Nuray Aktay
    Besbas, Nesrin
    Ozen, Seza
    ARTHRITIS CARE & RESEARCH, 2010, 62 (01) : 73 - 77
  • [38] A cost-efficacy analysis of subcutaneous anti-tumor necrosis factor therapy in the treatment of psoriatic arthritis
    Tandon, N.
    Kavanaugh, A.
    Han, C.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB6 - AB6
  • [39] Two-year longitudinal study of persistence to anti-tumor necrosis factor treatment among rheumatoid arthritis patients
    Tang, B.
    Rahman, M. I.
    Naim, A.
    Changolkar, A. K.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S775 - S776
  • [40] Two-year longitudinal study of persistence to anti-tumor necrosis factor treatment among rheumatoid arthritis patients
    Tang, B.
    Rahman, M., I
    Naim, A.
    Changolkar, A.
    VALUE IN HEALTH, 2008, 11 (03) : A264 - A264
12345